» Articles » PMID: 23776235

Smoke Carcinogens Cause Bone Loss Through the Aryl Hydrocarbon Receptor and Induction of Cyp1 Enzymes

Overview
Specialty Science
Date 2013 Jun 19
PMID 23776235
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Smoking is a major risk factor for osteoporosis and fracture, but the mechanism through which smoke causes bone loss remains unclear. Here, we show that the smoke toxins benzo(a)pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) interact with the aryl hydrocarbon receptor (Ahr) to induce osteoclastic bone resorption through the activation of cytochrome P450 1a/1b (Cyp1) enzymes. BaP and TCDD enhanced osteoclast formation in bone marrow cell cultures and gavage with BaP stimulated bone resorption and osteoclastogenesis in vivo. The osteoclastogenesis triggered by BaP or RANK-L was reduced in Ahr(-/-) cells, consistent with the high bone mass noted in Ahr(-/-) male mice. The receptor activator of NF-κB ligand (RANK-L) also failed to induce the expression of Cyp1 enzymes in Ahr(-/-) cells. Furthermore, the osteoclastogenesis induced by TCDD was lower in Cyp1a1/1a2(-/-) and Cyp1a1/1a2/1b1(-/-) cultures, indicating that Ahr was upstream of the Cyp enzymes. Likewise, the pharmacological inhibition of the Cyp1 enzymes with tetramethylsilane or proadifen reduced osteoclastogenesis. Finally, deletion of the Cyp1a1, Cyp1a2, and Cyp1b1 in triple knockout mice resulted in reduced bone resorption and recapitulated the high bone mass phenotype of Ahr(-/-) mice. Overall, the data identify the Ahr and Cyp1 enzymes not only in the pathophysiology of smoke-induced osteoporosis, but also as potential targets for selective modulation by new therapeutics.

Citing Articles

The role of aryl hydrocarbon receptor in the occurrence and development of periodontitis.

Wu L, Li X, Li J, Wang Y, Yang C, Zhao C Front Immunol. 2024; 15:1494570.

PMID: 39575260 PMC: 11580016. DOI: 10.3389/fimmu.2024.1494570.


Smoking-induced suppression of β-casein in milk is associated with an increase in miR-210-5p expression in mammary epithelia.

Chiba T, Takaguri A, Mikuma T, Kimura T, Maeda T Biochem Biophys Rep. 2024; 39:101773.

PMID: 39044768 PMC: 11263956. DOI: 10.1016/j.bbrep.2024.101773.


The Association Between Clozapine Plasma Concentration, CYP2D6 (*10, *2) Polymorphisms and Risk of Adverse Reactions.

Qu K, Zhou Q, Zhu H, Zhou Z, Shen Y, Tian L Psychiatry Clin Psychopharmacol. 2024; 33(2):76-83.

PMID: 38765922 PMC: 11082567. DOI: 10.5152/pcp.2023.22392.


The Role of Aryl Hydrocarbon Receptor in Bone Biology.

Vyavahare S, Ahluwalia P, Gupta S, Kolhe R, Hill W, Hamrick M Int J Tryptophan Res. 2024; 17:11786469241246674.

PMID: 38757095 PMC: 11097734. DOI: 10.1177/11786469241246674.


Bridging the Gap in Understanding Bone Metastasis: A Multifaceted Perspective.

Elaasser B, Arakil N, Mohammad K Int J Mol Sci. 2024; 25(5).

PMID: 38474093 PMC: 10932255. DOI: 10.3390/ijms25052846.


References
1.
Dragin N, Shi Z, Madan R, Karp C, Sartor M, Chen C . Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse. Mol Pharmacol. 2008; 73(6):1844-56. PMC: 2735564. DOI: 10.1124/mol.108.045658. View

2.
Nebert D, Karp C . Endogenous functions of the aryl hydrocarbon receptor (AHR): intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology. J Biol Chem. 2008; 283(52):36061-5. PMC: 2606007. DOI: 10.1074/jbc.R800053200. View

3.
Lindsey S, Papoutsakis E . The evolving role of the aryl hydrocarbon receptor (AHR) in the normophysiology of hematopoiesis. Stem Cell Rev Rep. 2012; 8(4):1223-35. PMC: 3463730. DOI: 10.1007/s12015-012-9384-5. View

4.
Abe E, Marians R, Yu W, Wu X, Ando T, Li Y . TSH is a negative regulator of skeletal remodeling. Cell. 2003; 115(2):151-62. DOI: 10.1016/s0092-8674(03)00771-2. View

5.
Zaidi M . Skeletal remodeling in health and disease. Nat Med. 2007; 13(7):791-801. DOI: 10.1038/nm1593. View